Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

67.15 +0.14 (+0.21%)
Streaming Delayed Price Updated: 1:51 PM EDT, Aug 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,018,238
Open 67.41
Bid (Size) 67.15 (200)
Ask (Size) 67.17 (700)
Prev. Close 67.01
Today's Range 66.45 - 67.41
52wk Range 42.52 - 68.64
Shares Outstanding 2,222,113,553
Dividend Yield 3.75%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset? ↗
IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk. 
Via The Motley Fool
Topics ETFs
News headline image
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Oc... 
Via StockStory
Topics Artificial Intelligence Intellectual Property

Performance

YTD
+25.6%
+25.6%
1 Month
+8.1%
+8.1%
3 Month
+15.7%
+15.7%
6 Month
+9.6%
+9.6%
1 Year
+42.4%
+42.4%

More News

Read More
News headline image
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now ↗
Via The Motley Fool
Bristol-Myers Squibb (NYSE:BMY) Surges on Q2 Earnings Beat, Raises Full-Year Guidance ↗
Via Chartmill
Topics Earnings
News headline image
1 Momentum Stock on Our Buy List and 2 We Turn Down
Via StockStory
News headline image
Are Mega-Mergers Back? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? ↗
Via The Motley Fool
News headline image
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
From Bristol Myers Squibb
Via Business Wire
News headline image
Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
From Bristol Myers Squibb
Via Business Wire
News headline image
1 Profitable Stock with Impressive Fundamentals and 2 We Avoid
Via StockStory
News headline image
Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
News headline image
Bristol-Myers Squibb (BMY) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Which S&P500 stocks are moving before the opening bell on Monday? ↗
Via Chartmill
News headline image
Bristol Myers Squibb Isn't Nearly as Cheap as It Looks -- Here's the 1 Thing That Could Change That ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
BMY Q2 Deep Dive: Growth Portfolio and Pipeline Progress Drive Upgraded Outlook
Via StockStory
News headline image
Bristol-Myers Squibb (BMY) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Why Bristol Myers Squibb Stock Topped the Market on Thursday ↗
Via The Motley Fool
News headline image
Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About ↗
Via The Motley Fool
Topics Lawsuit
News headline image
Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales
Via StockStory
News headline image
Bristol Myers Squibb Reports Second Quarter Financial Results for 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q2 Results Tomorrow
Via StockStory

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 67.15
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 08/24/26 01:51 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 149.21B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 149B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.